Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Open-label Single-arm Study to Evaluate the Combination of Pembrolizumab, Lenvatinib and Chemotherapy in Non-small Cell Lung Cancer (NSCLC) Harbouring Targetable Mutation and Failed Standard Tyrosine Kinase Inhibitors

NCT04989322 is registered in ClinicalTrials.gov with Dr Joanne CHIU as lead sponsor.

NCT NCT04989322
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04989322 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Open-label Single-arm Study to Evaluate the Combination of Pembrolizumab, Lenvatinib and Chemotherapy in Non-small Cell Lung Cancer (NSCLC) Harbouring Targetable Mutation and Failed Standard Tyrosine Kinase Inhibitors
Lead sponsor
Dr Joanne CHIU
Phase
Phase 2
Overall status
Unknown status
Start date
October 5, 2021
Completion date
December 31, 2024
Enrollment
46 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alk gene rearrangement positive, egf-r positive non-small cell lung cancer, egfr activating mutation, nsclc, ros1 gene rearrangement, ros1 positive nsclc - reactive oxygen species 1 positive non-small cell lung cancer